Nelio® 2,5 mg: Benazepril hydrochloride 2,5 mg.
Nelio® 5 mg: Benazepril hydrochloride 5 mg.
Nelio® 20 mg: Benazepril hydrochloride 20 mg.
Benazepril hydrochloride is a prodrug hydrolyzed in vivo to its active metabolite, benazeprilato. Benazeprilat is a highly potent selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing aldosterone synthesis. Therefore, it blocks the effects mediated by angiotensin II and aldosterone, including arterial and venous vasoconstriction, retention of sodium and water by the kidneys and remodeling effects (including pathologic cardiac hypertrophy and degenerative renal changes).
In dogs with congestive heart failure, it reduces blood pressure and heart burden.
In cats with renal failure, normalizes elevated glomerular capillary pressure and reduces systemic blood pressure. Reduction of glomerular hypertension may delay the progression of renal disease by inhibiting the added damage to the kidneys.
INTERACTIONS AND INCOMPATIBILITIES
• In dogs with congestive heart failure, the drug has been given in combination with digoxin, diuretics, pimobendan and antiarrhythmics without evidence of associated adverse reactions.
• Joint use of NSAIDs or other drugs with a hypotensive effect should be considered with caution.
• Monitor plasma levels of potassium when the drug is used in combination with a potassium-sparing diuretic because of the risk of hyperkalemia (high blood potassium level).
INDICATIONS AND SPECIES OF DESTINATION
Dogs: Treatment of congestive heart failure.
Cats: Reduced proteinuria associated with chronic kidney disease.
• Hypersensitivity to the active substance or to any excipients.
• Cases of hypotension, hypovolemia, hyponatremia or acute renal failure.
• Cases of falling cardiac output due to aortic or pulmonary stenosis.
Gestation and lactation: The safety of benazepril in these periods has not been established.
• In animals with chronic kidney disease, a moderate increase in plasma creatinine levels may occur. This is probably due to the effect of the treatment on the reduction of blood pressure in the kidney and, therefore, is not necessarily a reason to discontinue treatment, unless the animal has other adverse reactions.
• In cats, food consumption and weight may increase. Vomiting, anorexia, dehydration, lethargy, and diarrhea have rarely occurred.
• In some dogs with congestive heart failure, vomiting or fatigue may occur during treatment.
Administration way: Oral.
• The tablets are flavored and are voluntarily ingested by most dogs and cats.
No customer reviews for the moment.